Blog pages will comment on many aspects of drug development, in Infectious Diseases and other areas of interest and expertise.
Views expressed are based on my reading of the literature and my understanding of the context that impact development projects:
Preclinical science (toxicology, safety pharmacology, microbiology), animal and human PK and PK/PD relationships, human safety and efficacy data, regulatory considerations, policies and guidelines, clinical practice, and market forces.
The emphasis will be on new antibiotics in the pipeline. Information and views are provided without commercial slant and based on published information only.
This site does not accept advertising or promotional content and will always defend its staunchly independent character